Extended-interval dosing of aminoglycoside antibiotics in critically ill patients

Journal of Pharmacy Practice

Volumn 15, Issue 2, 2002, Pages 85-95

  Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Aminoglycosides; Critically ill; Once daily aminoglycosides; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; CRITICAL ILLNESS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; POSTANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; TREATMENT FAILURE;

EID: 0036089023     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1106/WKHR-J8JL-FHU5     Document Type: Article

References (76)

1. National survey of extended-interval aminoglycoside dosing
2. Once-daily aminoglycoside therapy
3. Aminoglycoside dosage regimens. Is once a day enough?
4. Once-daily administration of aminoglycosides
5. Single daily dosing of aminoglycosides
6. The pharmacodynamics of aminoglycosides
7. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia
8. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia
9. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia
10. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
11. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
12. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides
13. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use
14. Aminoglycoside adaptive resistance
15. Aminoglycoside ototoxicity: Influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features
16. Aminoglycosides: Nephrotoxicity
17. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety
18. Single or multiple daily doses of aminoglycosides: A meta-analysis
19. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
20. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
21. Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials
22. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis
23. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
24. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
25. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review
26. Initial aminoglycoside levels in the critically ill
27. Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia
28. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care
29. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients
30. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis
31. Altered aminoglycoside clearance in the critically ill
32. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients
33. Aminoglycoside pharmacokinetics: Dosage requirements and nephrotoxicity in trauma patients
34. A prospective randomized trial comparing individualized pharmacokinetic dosing prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients
35. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients
36. Aminoglycoside dosing considerations in intensive care unit patients
37. Physiologic response of stress and aminoglycoside clearance in critically ill patients
38. Aminoglycoside volume of distribution and illness severity in critically ill septic patients
39. Determination of plasma concentrations of amikacin in patients of an intensive care unit
40. Gentamicin: Is loading with 3 mg/kg enough
41. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient
42. Is 4 mg/kg an adequate loading dose for gentamicin/tobramycin in critically ill surgical patients?
43. A prospective evaluation of the predictive performance of an aminoglycoside pharmacokinetic program in Asian surgical intensive care patients
44. Wide variation in peak concentrations and length of aminoglycoside-free interval associated with single daily dose aminoglycoside regimens in 52 burn patients
45. Alternative aminoglycoside dosing in neurointensive care unit (NICU) patients
46. Assessment of the appropriateness of once-daily aminoglycoside dosing in surgical intensive care unit patients
47. Intrapatient variability of aminoglycoside pharmacokinetic parameters in simulated extended-interval aminoglycoside dosing
48. Once-daily aminoglycoside dosing for critically ill patients with renal insufficiency
49. Once-daily aminoglycoside dosing protocol results in inadequate gentamicin levels in surgical intensive care unit patients with normal renal function
50. Once-daily aminoglycoside dosing (7 mg/kg) in surgical ICU patients fails to achieve therapeutic target peak levels
51. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens
52. Dosage of once-daily gentamicin in spinal cord injury patients
53. Once daily aminoglycoside dosing (7 mg/kg) in the medical intensive care unit patient
54. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
55. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing
56. Once versus thrice daily gentamicin in patients with serious infections
57. Netilmicin in the treatment of gram-negative bacteremia: Single daily versus multiple daily dosage
58. Once- versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: A randomized, controlled study of efficacy and safety
59. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections
60. Does administration of an aminoglycoside in a single daily dose affect its efficacy and safety?
61. Aminoglycoside nephrotoxicity: Comparative assessment in critically ill patients
62. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients
63. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients
64. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides
65. Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides
66. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy
67. What is the cost of nephrotoxicity associated with aminoglycosides?
68. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
69. Effect of single daily dose vs. multiple daily dosing of tobramycin on alanine aminopeptidase and N-acetyl-β-D-glucosaminidase excretion
70. Does once-daily dosing of aminoglycosides affect neuromuscular function?
71. Aminoglycosides
72. Pharmacoeconomic evaluation of once-daily aminoglycoside treatment
73. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin
74. Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring
75. Pharmacoeconomic impact of once-daily aminoglycoside administration
76. Once-daily dosing of aminoglycosides. A consensus document